Overview

A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
ST-1891 is a multicenter, randomized, double-blind, crossover, Phase 2 study evaluating the safety and efficacy of hormone replacement therapy with ST-1891 compared to levothyroxine in patients with primary hypothyroidism.
Phase:
Phase 2
Details
Lead Sponsor:
Sention Therapeutics, LLC